PubMed Health⌕ Search

PubMed · 14750402

Preventing medication errors with smart infusion technology.

Abstract

PURPOSE: Processes that pharmacists can use to identify high-risk areas and drugs that require special focus in error-prevention efforts are discussed, with emphasis on the need for i.v. medication error prevention. SUMMARY: Pharmacists can help determine where best to focus medication safety efforts and innovative technology by identifying areas that pose the greatest risk of harm to a patient, such as medications, administration routes, patient care areas, and diagnosis-related groups. Delivery of i.v. medications via infusion devices has traditionally not been a major concern for pharmacists. The introduction of "smart" infusion technology has changed that paradigm by requiring pharmacist involvement in defining minimum and maximum doses for continuous and bolus infusions used within a health care facility. This technology provides a software filter to prevent key-stroke errors in programming infusion devices for delivery of i.v. drugs, as well as a new source of data with which to measure medication errors at the bedside. Implementation of smart infusion technology at Vanderbilt University Medical Center appeared to prevent errors involving heparin. In addition to having an immediate positive impact at the bedside, the technology was relatively easy to implement. CONCLUSION: Smart infusion systems represent an innovative technology that can provide an additional layer of protection at the point of care to help avert i.v. drug errors and prevent patient harm.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Karen Wilson, Mark Sullivan. 2004-01-15. Preventing medication errors with smart infusion technology.. https://doi.org/10.1093/ajhp%2F61.2.177

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Exploring options for improving healthcare.

New medical technologies generally must receive clearance or approval for marketing by the US Food and Drug Administration and be covered by an insurer, such as the Centers for Medicare and Medicaid Services, before becoming available for widespread clinical use. These 2 approval processes are discrete and usually occur sequentially rather than collaboratively and simultaneously. To explore potential mechanisms for increasing regulatory collaboration between these 2 key health care agencies, the Duke Clinical Research Institute and Health Strategies Consultancy convened an informal meeting of agency, academic, and industry leaders on December 8 and 9, 2002, titled "Registration/Approval and Coverage/Payment: Exploring Options for Improving Healthcare." This article arises from the discussion at this conference; it does not represent the official views of any person or institution involved. Although the group did not attempt to reach a consensus, it examined several important issues surrounding this regulatory debate. Herein are proposed options for enhancing regulatory efficiency through greater coordination between the FDA and CMS, and discussion of these proposals from the perspectives of members of both agencies, members of stakeholder organizations, and academic observers.

Biomedical Technology↗